Rockefeller Capital Management L.P. Cyma Bay Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$3.22 - $6.27 $609,224 - $1.19 Million	-189,200 Reduced 88.33%	25,000 $156,000
Q2 2022 Aug 12, 2022	SELL	$1.72 - $3.39 $22,661 - $44,663	-13,175 Reduced 5.79%	214,200 $631,000
Q1 2022 May 13, 2022	BUY	$2.77 - $3.64 $1,454 - $1,911	525 Added 0.23%	227,375 $707,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $332,205 - $473,109	102,850 Added 82.94%	226,850 $766,000
Q3 2021 Nov 12, 2021	BUY	$3.47 - $4.42 $86,750 - $110,500	25,000 Added 25.25%	124,000 $452,000

Q2 2021 Aug 10, 2021	BUY	$3.94 - $4.92 $390,060 - $487,080	99,000 New	99,000 $431,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.